According to the most recent official numbers, India's out-of-pocket spending (OOPE) on healthcare has steadily decreased, but the country's poorest families continue to bear some of the highest personal medical costs in the world when compared to nations of comparable economic status. While the figures are improving, public health experts contend that the lived reality for regular patients—particularly women carers, the elderly, and low-income households—is still significantly more complex. 

According to the National Health Accounts, OOPE as a percentage of Total Health Expenditure (THE) has declined dramatically, from 62.6 percent in 2014-15 to 39.4 percent in 2021-22. This means that citizens are now directly paying a lesser proportion of the nation's total healthcare spending than they were a decade earlier. The government informed Parliament that India ranks 69th out of 189 countries in terms of purchasing power for personal health spending. Several nations with similar income levels, notably Indonesia, Vietnam, and the Philippines, have lower OOPE percentages because public funding and insurance coverage are more evenly distributed throughout primary, secondary, and preventive care. 

The government asserts the drop on increased public investment. Government health expenditure has increased from 29 per cent of total expenditure in 2014-15 to 48 per cent in 2021-22, owing to increased state-level grants and Union schemes. "The budget allocation for the Department of Health and Family Welfare has increased by 174 percent between 2013-14 and 2025-26," the minister stated, adding that the Fifteenth Finance Commission approved Rs. 70,051 crore for the health sector. 

To alleviate patients' financial burdens, the National Health Mission (NHM) has increased services such as Ayushman Arogya Mandirs, ambulance networks, mobile medical units, free drug distribution, and free diagnostics. The Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) now provides Rs. 5 lakh in annual coverage to nearly 12 crore families, as states expand eligibility. In 2024, around 37 lakh ASHA and Anganwadi households will be included, and six crore elderly adults aged 70 and up will be enrolled in the Vay Vandana Card. 

Drug pricing has also been a contentious issue. The National Pharmaceutical Pricing Authority (NPPA) has set ceiling pricing for 935 important formulations and announced retail prices for more than 3,600 new medications. Successful price controls on stents, knee implants, and certain cancer drugs have resulted in predicted yearly savings of up to Rs. 25,000 crore. Meanwhile, Janaushadhi Kendras, which now number over 17,000, have saved Rs. 40,000 crore over the last eleven years by supplying generic medicines at 50 to 80 percent lower pricing. 

However, OOPE remains a critical concern. The average yearly price increase for non-scheduled drugs is 5.6 per cent, and deficiencies in public infrastructure drive many families to private clinics. These costs quickly build up for women, who frequently manage household health, and the elderly, who have various chronic ailments. 

While India has made significant progress, experts generally believe that really low-OOPE healthcare will necessitate greater primary care strengthening, more cheap diagnostics, and consistent drug availability across states.